您的位置: 首页 > 农业专利 > 详情页

Biomarkers for cancer therapeutics
专利权人:
Merck Sharp & Dohme Corp.;Amgen Inc.
发明人:
Gansert, Jennifer Lorraine,Anderson, Abraham Antonio,Gorski, Kevin
申请号:
AU2018260777
公开号:
AU2018260777A1
申请日:
2018.04.27
申请国别(地区):
AU
年份:
2019
代理人:
摘要:
Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充